Medicare 'negotiation' in NJ is not negotiation - Insurance News | InsuranceNewsNet

InsuranceNewsNet — Your Industry. One Source.™

Sign in
  • Subscribe
  • About
  • Advertise
  • Contact
Home Now reading Health/Employee Benefits News
Topics
    • Advisor News
    • Annuity Index
    • Annuity News
    • Companies
    • Earnings
    • Fiduciary
    • From the Field: Expert Insights
    • Health/Employee Benefits
    • Insurance & Financial Fraud
    • INN Magazine
    • Insiders Only
    • Life Insurance News
    • Newswires
    • Property and Casualty
    • Regulation News
    • Sponsored Articles
    • Washington Wire
    • Videos
    • ———
    • About
    • Meet our Editorial Staff
    • Advertise
    • Contact
    • Newsletters
  • Exclusives
  • NewsWires
  • Magazine
  • Newsletters
Sign in or register to be an INNsider.
  • AdvisorNews
  • Annuity News
  • Companies
  • Earnings
  • Fiduciary
  • Health/Employee Benefits
  • Insurance & Financial Fraud
  • INN Exclusives
  • INN Magazine
  • Insurtech
  • Life Insurance News
  • Newswires
  • Property and Casualty
  • Regulation News
  • Sponsored Articles
  • Video
  • Washington Wire
  • Life Insurance
  • Annuities
  • Advisor
  • Health/Benefits
  • Property & Casualty
  • Insurtech
  • About
  • Advertise
  • Contact
  • Editorial Staff

Get Social

  • Facebook
  • X
  • LinkedIn
Health/Employee Benefits News
Health/Employee Benefits News RSS Get our newsletter
Order Prints
June 24, 2024 Health/Employee Benefits News
Share
Share
Post
Email

Medicare 'negotiation' in NJ is not negotiation

Sandip Shah, Special to the USA TODAY NetworkHerald News

For 2024, New Jersey seniors had access to about 20 standalone Medicare Part D prescription drug plans, plus dozens more Medicare Advantage options. For years, tough bargaining between drug makers and insurers over these plans delivered value and choice to our seniors.

Under the Inflation Reduction Act, the federal government received new authority to start "negotiating" the price of prescription drugs in Medicare. The Centers for Medicare & Medicaid Services began its Drug Price Negotiation Program with ten drugs this year. The program will expand annually, reaching 20 new drugs each year starting in 2029.

But the IRA's terminology isn't right. The process won't be a "negotiation" at all. I've been at the table in drug price negotiations between manufacturers and payers, and this is nothing of the kind. Rather, the framework the IRA sets out gives CMS price-setting power, whether drug makers like it or not.

We all know what a negotiation looks like: Both buyer and seller are free to walk away at any time. If you can't get the car price you want from Dealer A, you can take the jug-handle down the road to Dealer B. Likewise, the dealer can refuse to sell at your price. Both sides have power. This is the dynamic at work when insurers negotiate with biopharmaceutical companies.

Before the IRA, the government wasn't allowed to negotiate with drug companies. That meant that all price negotiations took place in the voluntary and competitive private sector.

In these true negotiations, drug makers offer discounts for favorable placement on insurer "formularies" — which can mean more sales relative to competitors. Insurers work through pharmacy benefit managers, who have significant leverage to push for large discounts. New data show these private negotiations have led to discounts of 53% off list prices on average.

But the so-called negotiations under the IRA won't work at all like negotiation in this highly successful private market. Let's see why:

First, in the private market, manufacturers are able to walk away from a negotiation without losing practically the entire commercial market in the case of drugs taken mainly by older Americans. Here, we have CMS on one side of the table, buying for 67 million people, and individual drug makers with nowhere else to sell on the other side. CMS has enormous power to get what it wants from any vendor. Further, the IRA requires that if a drug maker refuses to negotiate, it faces an excise tax of 95% of all revenue from sales of that drug. The only way a drug maker can avoid this confiscatory penalty is to withdraw its products from not just Medicare but also Medicaid, which covers 84 million additional beneficiaries. In other words, the government can shut off its ability to sell products to about half the adult population. This lopsided power dynamic does not reflect how negotiations work in the private sector.

Second, several years down the road, should CMS decide that it does not like the price it set for a drug, it has broad authority to "renegotiate" — in other words, force the manufacturer back to the table and take a lower price. This contrasts with the private market, in which either the buyer or seller can offer reasons to renegotiate, but deals only get done if they agree on terms.

Third, private market negotiation has two main issues to settle — the price and how that drug is covered by the insurer. In contrast, Medicare negotiation is limited to just one issue, price. CMS makes no commitment to guaranteeing patients ready access to drugs subject to negotiation.

Fourth, private payers actively seek expert clinical input from physicians often in the form of what's commonly known as a "P&T" or pharmacy and therapeutics committee. Clinician voices are critical to understanding the benefit and value of a medicine. CMS has failed to create a formal process for such input.

The IRA has radically changed the Medicare prescription drug benefit. Dubbing it a negotiation only obscures the reality of a process in which the government is calling all the shots.

Sandip Shah, a visiting professor at Rutgers University, is founder and president of Market Access Solutions, which develops strategies to optimize patient access to life-changing therapies.

Older

Joseph Stiglitz: "We still have time to save capitalism from itself, but if Trump wins it will be harder."

Newer

State Sen. Harris chairs insurance committee, invests in insurance brokers. Isn't that a conflict?

Advisor News

  • Survey: Most Americans still feel prosperous despite economic worries
  • SEC settlement would require Tai Lopez, two others, to pay $6.8 million
  • The Gen Z money paradox
  • NAIFA applauds final SECURE 2.0 regulations
  • What will Democrats in Congress do about healthcare and retirement?
More Advisor News

Annuity News

  • AM Best Affirms Credit Ratings of Global Atlantic Financial Group Limited and Its Subsidiaries
  • Best’s Market Segment Report: AM Best Maintains Stable Outlook on US Life/Annuity Insurance Segment
  • AM Best Affirms Credit Ratings of Massachusetts Mutual Life Insurance Company and Its Subsidiaries
  • Boomers want retirement protection, but their actions don’t match their mindset
  • NAIC task force to address LTC riders
More Annuity News

Life Insurance News

  • AM Best Affirms Credit Ratings of Ameriprise Financial, Inc. and Its Subsidiaries
  • AM Best Takes Various Credit Rating Actions on Certain Subsidiaries of Auto-Owners Insurance Group
  • AM Best Affirms Credit Ratings of Global Atlantic Financial Group Limited and Its Subsidiaries
  • AM Best Downgrades Credit Ratings of CICA Life Insurance Company of America
  • AM Best Upgrades Credit Ratings of CTBC Insurance Company Ltd
More Life Insurance News

Property and Casualty News

  • AM Best Affirms Credit Ratings of Ameriprise Financial, Inc. and Its Subsidiaries
  • AM Best Affirms Credit Ratings of NongHyup Property and Casualty Insurance Company Limited
  • AM Best Affirms Credit Ratings of Delphi Financial Group, Inc. and Its Subsidiaries; Upgrades Issuer Credit Rating of Standard Security Life Insurance Company of New York
  • State Farm, Wests, State settle lawsuits
  • November Issue of Best’s Review Ranks US Life Reinsurers and More
More Property and Casualty News

NEWS INSIDE

  • Companies
  • Earnings
  • Economic News
  • INN Magazine
  • Insurtech News
  • Newswires Feed
  • Regulation News
  • Washington Wire
  • Videos

FEATURED OFFERS

Press Releases

  • OpenRoad Insurance Data Shows 40% of Collector Vehicles Are Model Year 1980 or Newer
  • Insurvoice Lets Independent Insurance Agency Owners Analyze Every Customer Call in ChatGPT or Claude
  • Spectrum Weather & Specialty Insurance Celebrates 15 Years and Welcomes the Next Generation
  • Royal Neighbors of America® Increases Service Capacity
  • Benefits Studio Launches to Fill the Missing Middle of Benefits Navigation at $49/mo
More Press Releases > Add Your Press Release >

How to Write For InsuranceNewsNet

Find out how you can submit content for publishing on our website.
View Guidelines

Topics

  • Advisor News
  • Annuity Index
  • Annuity News
  • Companies
  • Earnings
  • Fiduciary
  • From the Field: Expert Insights
  • Health/Employee Benefits
  • Insurance & Financial Fraud
  • INN Magazine
  • Insiders Only
  • Life Insurance News
  • Newswires
  • Property and Casualty
  • Regulation News
  • Sponsored Articles
  • Washington Wire
  • Videos
  • ———
  • About
  • Meet our Editorial Staff
  • Advertise
  • Contact
  • Newsletters

Top Sections

  • AdvisorNews
  • Annuity News
  • Health/Employee Benefits News
  • InsuranceNewsNet Magazine
  • Life Insurance News
  • Property and Casualty News
  • Washington Wire

Our Company

  • About
  • Advertise
  • Contact
  • Meet our Editorial Staff
  • Magazine Subscription
  • Write for INN

Sign up for our FREE e-Newsletter!

Get breaking news, exclusive stories, and money- making insights straight into your inbox.

select Newsletter Options
Facebook Linkedin Twitter
© 2026 InsuranceNewsNet.com, Inc. All rights reserved.
  • Terms & Conditions
  • Privacy Policy
  • InsuranceNewsNet Magazine

Sign in with your Insider Pro Account

Not registered? Become an Insider Pro.